Epidemiology and management of malignancies in patients with inborn errors of immunity—An ESID registry study of 19,959 patients
Journal of Allergy and Clinical Immunology · 2026-03 · 157 (3) · 739-753
DOI: 10.1016/j.jaci.2025.10.033 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Allergy and Clinical Immunology, 2026-03. Verfasst von Delfien J A Bogaert und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Hematology-Oncology, Department of Pediatrics, University Hospital Brussels (UZ Brussel), Brussels, Belgium; National Children'…. Hauptthemen laut MEDLINE: Neoplasms, Primary Immunodeficiency Diseases. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Princess Máxima Center for Pediatric Oncology.
Abstract (Originalsprache)
BACKGROUND: Inborn errors of immunity (IEI), or primary immune disorders (PIDs), predispose individuals to infections, autoimmunity, inflammation, allergy, and malignancy. Malignancies are a major cause of morbidity and mortality in patients with IEI/PIDs, with poorer outcomes compared with the general population. OBJECTIVE: We sought to determine the frequency and types of malignancies in patients with IEI/PIDs and to assess clinical management approaches across Europe. METHODS: Descriptive analyses were performed on malignancy data within each IEI category. In addition, a European Society for Immunodeficiencies Registry survey (05/2022-03/2024) collected data on management strategies and challenges. RESULTS: Of 19,959 patients with IEI/PIDs, 1783 (8.9%) developed malignancies, of whom 27.1% presented malignancy as first manifestation of IEI/PIDs. A total of 1210 malignancies were specified; B-cell non-Hodgkin lymphoma was most common (24.2%). Detailed malignancy-IEI/PID association maps are provided. Predominantly antibody deficiencies accounted for 59.1% of malignancy cases, with a higher median age at first malignancy (43.6 years) compared with other IEI/PID categories, for example, combined immunodeficiencies with syndromic or associated features (11.7 years). Survey findings revealed that oncological treatment was modified because of IEI/PIDs in 21.5% of cases, with assumed negative impacts of IEI/PIDs on complications and outcomes (in 27.4% and 30.7%, respectively). IEI/PIDs influenced transplant decisions in 16.5% of cases. Management practices such as interdisciplinary decision finding and guideline availability were recorded. CONCLUSIONS: This study provides comprehensive epidemiological data on malignancies in IEI/PIDs, highlighting the need for tailored screening and management. Survey results emphasize the real-world challenges and support the development of IEI/PID-specific oncological surveillance guidelines and treatment strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Pediatric Hematology-Oncology, Department of Pediatrics, University Hospital Brussels (UZ Brussel), Brussels, Belgium; National Children's Cancer Service, Children's Health Ireland at Crumlin, Dublin, Irelan…
- Styrian Children's Cancer Research Unit for Cancer and Inborn Errors of the Blood and Immunity in Children, Graz, Austria; Division of Neonatology, Department of Pediatrics and Adolescent Medicine, Medical University of…
- St Anna Children's Hospital, Medical University of Vienna, Vienna, Austria; St Anna Children's Cancer Research Institute, Vienna, Austria.
- Institute for Immunodeficiency, Center for Chronic Immunodeficiency, Freiburg, Germany; Centre for Biobanking FREEZE, Freiburg, Germany.
- Institute for Immunodeficiency, Center for Chronic Immunodeficiency, Freiburg, Germany; Clinic of Rheumatology and Clinical Immunology, Center for Chronic Immunodeficiency, Medical Center, Faculty of Medicine, Universit…
- Institute for Immunodeficiency, Center for Chronic Immunodeficiency, Freiburg, Germany.
Förderung
- Princess Máxima Center for Pediatric Oncology
Zitieren
APA
Bogaert, D. J. A., Wolfsberger, C. H., Attarbaschi, A., Gathmann, J., Warnatz, K., Mueller, G., Mukhina, A., Rusch, S., ESID Registry Working Party, Kindle, G., van Montfrans, J. M., & Seidel, M. G. (2026). Epidemiology and management of malignancies in patients with inborn errors of immunity—An ESID registry study of 19,959 patients. Journal of Allergy and Clinical Immunology, 157(3), 739-753. https://doi.org/10.1016/j.jaci.2025.10.033
Vancouver
Bogaert DJA, Wolfsberger CH, Attarbaschi A, Gathmann J, Warnatz K, Mueller G, et al. Epidemiology and management of malignancies in patients with inborn errors of immunity—An ESID registry study of 19,959 patients. Journal of Allergy and Clinical Immunology. 2026;157(3):739-753. doi:10.1016/j.jaci.2025.10.033
BibTeX
@article{Bogaert2026,
author = {Bogaert, Delfien J A and Wolfsberger, Christina H and Attarbaschi, Andishe and Gathmann, Jonathan and Warnatz, Klaus and Mueller, Gabriele and Mukhina, Anna and Rusch, Stephan and ESID Registry Working Party, ESID Registry Working Party and Kindle, Gerhard and van Montfrans, Joris M and Seidel, Markus G},
title = {Epidemiology and management of malignancies in patients with inborn errors of immunity—An ESID registry study of 19,959 patients},
journal = {Journal of Allergy and Clinical Immunology},
year = {2026},
volume = {157},
number = {3},
pages = {739--753},
doi = {10.1016/j.jaci.2025.10.033}
}
EUVIMED